Insights

AmerisourceBergen

Our Look at "American Patients First"

Inverted color AmerisourceBergen icon
AmerisourceBergen
May 2018

Experts from AmerisourceBergen take a look at what President Trump's new plan for reducing drug prices means for manufacturers to pharmacies and the drug wholesale industry.

AmerisourceBergen

A New Approach to Channel Strategy for Oncology Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

How is manufacturer thinking around channel strategy changing for oral oncolytics?

AmerisourceBergen

Full-line vs. Specialty Distribution

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

What manufacturers need to know about how distribution impacts access.

AmerisourceBergen

Upping the Game

Kristin Chambers
April 2018

How drug manufacturers, health systems and payers can collaborate more closely in the new world of patient-centered care.

AmerisourceBergen

Caring for the Whole Patient

Kristin Chambers
April 2018

The growing trend toward value-based payment models and ongoing demand for clinical outcomes creates a need for better coordination of care. What challenges does this create for health system specialty pharmacies and what opportunities does this present for demonstrating value?

AmerisourceBergen

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

Insights from managed care executives on the future of coverage and outcomes evaluation.

Xcenda

Seeing the Value and Transparency of Medicare Part B

Jennifer Snow, MPH
April 2018

AmerisourceBergen

Payer Perspectives on the Cost of Copay Programs

Corey Ford
Corey Ford, MHA
March 2018

Xcenda examines payer tactics for managing commercial copay assistance in a new issue brief.

AmerisourceBergen

One Size Does Not Fit All

Susan Stinson
March 2018

Expert perspectives on how patient engagement and adherence strategies are evolving to meet each individual’s unique needs.

AmerisourceBergen

Distribution Decisions

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2018

How do manufacturers' distribution decisions ultimately impact patients? What long- and short-term disruption do direct models present? AmerisourceBergen experts offer perspective on the unintended consequences of channel strategy decisions.

AmerisourceBergen

2018 Healthcare Outlook

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2018

Key healthcare and health policy trends to watch in 2018 -- and what they mean for pharmaceutical manufacturers.

AmerisourceBergen

Leadership in Specialty

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2018

Our strategic global sourcing experts share how AmerisourceBergen's leadership in specialty distribution influences the way we partner with manufacturers.

AmerisourceBergen

An Inside Look at the Customer Experience

Inverted color AmerisourceBergen icon
AmerisourceBergen
January 2018

Our experts share what customers wish manufacturers knew about product access.

AmerisourceBergen

Rethinking Reimbursement and Patient Support Following Medical Innovation

Amy Grogg
Amy Grogg
January 2018

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

AmerisourceBergen

The Downstream Impact of Channel Strategy Decisions

Inverted color AmerisourceBergen icon
AmerisourceBergen
January 2018

What manufacturers need to know about the customer experience.

AmerisourceBergen

Information Exchange With Payers and Providers

Inverted color AmerisourceBergen icon
AmerisourceBergen
January 2018

What information do payers and providers want from pharma?

AmerisourceBergen

Four Questions That Will Move Pharma Forward

Inverted color AmerisourceBergen icon
AmerisourceBergen
December 2017

Key themes from ThinkLive 2017, AmerisourceBergen's annual manufacturer summit.

AmerisourceBergen

Effective Distribution Partnerships

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2017

How an effective pharmaceutical distribution partnership works.

AmerisourceBergen

How Wholesalers Have Evolved in Recent Years

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2017

How pharmaceutical wholesalers have evolved in recent years.

AmerisourceBergen

Improving Patient Services and Outcomes With Data-Driven Design

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How can data-driven service design improve patient support programs and outcomes?

AmerisourceBergen

The Growth of Biosimilars in the Oncology Pipeline

Dave Picard
September 2017

What should biosimilar manufacturers focus on for commercialization success?

AmerisourceBergen

Rethink: The Future of Benefit Verification

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

What does the future of benefit verification look like for manufacturer patient support programs?

AmerisourceBergen

Changing Channels

Donna Gilbert
September 2017

Learn the unintended consequences of channel strategy decisions and the impact on patients and providers.

AmerisourceBergen

What Do Payers Think About Digital Health Technologies

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How are payers thinking about apps, wearables and other digital health technologies?

Innomar Strategies

The Route to Market Access in Canada

Inverted color AmerisourceBergen icon
Innomar Strategies
September 2017

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

AmerisourceBergen

How to Get the Most From Outsourced Service Providers

Shanna Barnes
August 2017

Four things to keep in mind for patient support partnerships.

AmerisourceBergen

Improving Customer Experience and Driving Long-Term Value for Manufacturers

Rich Tremonte
August 2017

Rich Tremonte on the current healthcare landscape, the role of the wholesaler and how the new organizational structure at AmerisourceBergen brings out the best in both.

AmerisourceBergen

Biosimilar Coding

Amanda Forys
August 2017

Alternative methodologies for coding biosimilars reveal an addition $15.1 billion in hidden savings.

AmerisourceBergen

Add Value to Your Specialty Strategy

Randy Maloziec
July 2017

What should manufacturers look for in a specialty pharmacy partner? Learn six ways the right SP can add value.

AmerisourceBergen

Logistics Decisions Will Impact the Success of New Cell and Gene Therapies

Pete Belden
July 2017

In supply chain decisions, a wholly new type of product demands a wholly new definition for supply chain expertise and effective support.

AmerisourceBergen

Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
July 2017

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

AmerisourceBergen

Innovative Approaches to Improving Clinical Trial Success

Sam Herbert
April 2017

Sam Herbert, President of World Courier, shares the factors that are driving trial sponsors to deploy innovative approaches to manage expenses and improve trial success.

AmerisourceBergen

Practical Data in an Insights-driven World

Kevin Hallinan
March 2017

How should manufacturers be using distribution data to uncover insights and manage access?

AmerisourceBergen

Designing Patient-centric Support Programs

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2017

Explore what it means to put patients at the center of support program design through this interactive experience drawing perspective from real patients and how they view healthcare.

AmerisourceBergen

Understanding the Rare Disease Journey

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2017

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.

AmerisourceBergen

The Changing Role of 3PL Providers

Pete Belden
February 2017

Pete Belden, President of ICS, shares how the manufacturer client base for 3PL is changing as a result of the rapid expansion of emerging manufacturers and industry consolidation.

AmerisourceBergen

Orphan Drugs: Five Ways to Prove Product Value

Amy Grogg
Amy Grogg
February 2017

Demonstrate the value of rare disease therapies with these five key ways to connect where patients, physicians and payers perceive the most value.

AmerisourceBergen

Do's and Don'ts for Orphan Drug Support Programs

AmerisourceBergen icon
Nancy Pilcher
November 2016

The five components manufacturers shouldn't ignore when building orphan drug support programs.

AmerisourceBergen

Five Oncology Trends Impacting the Patient Experience

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2016

New challenges to oncology product access, optimized clinical outcomes and commercial success, with strategic recommendations for how pharmaceutical manufacturers can support prescribers and patients through the continuum of cancer care.

AmerisourceBergen

Patient-Centric Product Commercialization: Part Three

Amy Grogg
Amy Grogg
July 2016

Designing support programs that are truly patient-centric and overcoming obstacles along the way.

AmerisourceBergen

Patient-Centric Product Commercialization: Part Two

Amy Grogg
Amy Grogg
June 2016

Mapping the patient journey and building support programs that address the three biggest hurdles patients face.

AmerisourceBergen

Patient-Centric Product Commercialization: Part One

Amy Grogg
Amy Grogg
June 2016

How can manufacturers turn patient-centricity from buzzword into reality?

Innomar Strategies

The Future of Patient Assistance Programs in Canada

Sandra Anderson
Sandra Anderson
February 2016

As global manufacturers of specialty pharmaceuticals look to enter the Canadian market, it is important to understand the Canadian healthcare landscape with the provision of patient support services being an important consideration.

AmerisourceBergen

The Fundamentals of Commercialization Strategy

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2015

AmerisourceBergen

The Globalization of Pharma

Inverted color AmerisourceBergen icon
AmerisourceBergen
December 2014

The globalization of healthcare raises a number of questions for the pharmaceutical industry, from how R&D is changing to how to approach new markets.

AmerisourceBergen

The Evolution of GPO Contracting

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2014

How the Group Purchasing Organization (GPO) model has evolved — and what it means for manufacturers.